Scott Drew, DO
Hospitalist · Santa Cruz, CANPI 1952796047
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,700 of the $7,460 with a category attached, or 76.4%. Incyte Corporation accounts for 61.2% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $4,267, more than ten times the $38 reported in 2019. Among hospitalist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $219.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$5K
- UCB, Inc.$2K
- Journey Medical Corporation$287
- Galderma Laboratories, L.p.$258
- AbbVie$102
- Regeneron Healthcare Solutions, Inc.$82
- plus $164 from 3 others
What the payments were for
- Consulting fees$5,70076%
- Food & beverage$1,76024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 13 | $4,565 |
| UCB, Inc. | 2 | $2,002 |
| Journey Medical Corporation | 2 | $287 |
| Galderma Laboratories, L.p. | 10 | $258 |
| AbbVie | 1 | $102 |
| Regeneron Healthcare Solutions, Inc. | 1 | $82 |
| Novartis | 2 | $70 |
| Arcutis Biotherapeutics, Inc. | 2 | $68 |
| Johnson & Johnson | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,460 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 16 | $176 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $56 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Santa Cruz
- Jennifer SchneiderSanta Rosa$1.2M
- Soham ShahBakersfield$844K
- Alpesh AminOrange$428K
- Retha GoodglickSanta Monica$156K
- Robert WachterSan Francisco$75K
- Steven WongTorrance$36K
- Edward LeeLos Angeles$30K
- Anjani KolahiOrange$30K
- Omar AldaasSan Diego$24K
- Summaiya MuhammadCastro Valley$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.